
CRISPR Therapeutics AG (NASDAQ:CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.
The CRISPR Therapeutics Analyst: Kostas Biliouris initiated coverage of CRISPR Therapeutics with an Outperform rating and a price target of $98.